MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ
1.070
-0.050
-4.46%
Pre Market: 1.090 +0.02 +1.87% 09:16 12/18 EST
OPEN
1.100
PREV CLOSE
1.120
HIGH
1.130
LOW
1.060
VOLUME
26.67K
TURNOVER
0
52 WEEK HIGH
6.77
52 WEEK LOW
1.060
MARKET CAP
200.38M
P/E (TTM)
-4.8482
1D
5D
1M
3M
1Y
5Y
1D
Humacyte's US$28m Market Cap Fall Books Insider Losses
Simply Wall St · 1d ago
Humacyte Enters Sales Agreement with TD Securities
TipRanks · 1d ago
HUMACYTE: MAY OFFER AND SELL SHARES OF COMMON STOCK OF UP TO $60 MLN FROM TIME TO TIME THROUGH TD COWEN, ACTING AS AGENT
Reuters · 1d ago
Humacyte announces credit facility up to $77.5M
TipRanks · 2d ago
Humacyte Secures Up to $77.5 Million Credit Facility from Avenue Capital
Reuters · 2d ago
HUMACYTE ANNOUNCES CREDIT FACILITY OF UP TO $77.5 MILLION WITH AVENUE CAPITAL
Reuters · 2d ago
Press Release: Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
Dow Jones · 2d ago
Humacyte Secures $77.5 Million Loan Facility
TipRanks · 2d ago
More
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Webull offers Humacyte Inc stock information, including NASDAQ: HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.